… ProQR Update August 2022 Announced today (August 11, 2022), ProQR will focus exclusively on the development of the … from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 …
… Building an Inclusive ProQR At ProQR we strive to create an inclusive culture where everyone … logo to incorporate the pride rainbow flag. Pride month at ProQR is an opportunity to celebrate and thank all of the …
… ProQR welcomes a new generation of scientists Throughout the … The visit began with general presentations about ProQR, our history, and Axiomer™ RNA editing technology, as … of our innovative laboratories in Leiden, including the R&D, CMC and Histology departments, and the practical work …
… ProQR update and additional sepofarsen Illuminate trial analyses ProQR has announced the completion of an in-depth strategic … additional analyses of the sepofarsen *Illuminate* trial. ProQR has announced the completion of an in-depth strategic …
… ProQR driving an inclusive culture celebrating Pride Month In … Lead Talent Acquisition, Silvia Catellani, to talk about ProQR, Pride, and driving an inclusive culture for present and future ProQRians. In June we caught up with our Lead Talent …
… ProQR at TIDES to highlight our Axiomer® technology This month several ProQRians will attend the Oligonucleotide and Peptide … beyond. At this year’s TIDES Europe, Gerard Platenburg, ProQR Chief Scientific Officer, and co-founder, is presenting …
… Today marks an expansion of the ProQR and Lilly partnership In September 2021 ProQR announced a global licensing and research collaboration … originally announced in September 2021 , applied ProQR’s proprietary Axiomer® RNA editing platform to target …
… at the forefront of the Axiomer® technology development. ProQR’s Sr. Vice President Innovation makes his point about … idea and made resources available to perform the necessary R&D work. This was late 2014. The foundation for the Axiomer® …
